Amoxicillin and Clavulanate Potassium Tablet 625mg Sfda GMP ISO

Name: Amoxicillin and Clavulanate Potassium Tablet 625mg Sfda GMP ISO
Brand: REYOUNG PHARMACEUTICAL CO., LTD.
SKU: 756507342

Shandong, ChinaREYOUNG PHARMACEUTICAL CO., LTD.

US$1.10

1 Box

Sample price:US$0.00/piece.Request sample

Product profile

Customization

Available

Application

Antibiotic

Usage Mode

For oral administration

Model NO.

375mg 625mg 1000mg

Suitable for

Elderly, Children, Adult

State

Solid

Shape

Tablet

Type

Biological Products

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

H19994051

Packing-1

Alu-Alu, 7tablets/Blister, 2blister/Box

Packing-2

Alu-Alu, 10tablets/Blister, 2blisters/Box

Packing-3

Alu-Alu, 10tablets/Blister/Box, 10boxes/Bundle

Shleflife

3 Years

Transport Package

Alu-Alu,7tablet/Blister,2blister/Box,10boxe/Bundle

Specification

375mg, 625mg, 1g

Trademark

Reyoung

Origin

China Reyoung Pharma

HS Code

3004101900

Production Capacity

1000000000tablets/Year

Company profile

REYOUNG PHARMACEUTICAL CO., LTD.

Shandong, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 1997-01-01 CertifiedNearest Port: Qingdao PortAverage Response Time: ≤24h CertifiedTerms of Payment: LC, T/T, D/P

AI-Powered supplier vetting

SummaryREYOUNG PHARMACEUTICAL CO., LTD. is a China-based limited company established in 1998, with 4,950 employees and operations in Shandong. The supplier reports ISO 9001, ISO 14001, and OHSAS 18001 certifications, more than 10 production lines, 50 quality-control staff, and 370 years of combined R&D-engineer experience. Its stated manufacturing portfolio includes sterile raw materials, powders and liquids for injection, tablets, and capsules, with reported annual production above the stated threshold. The company identifies three factories, an extensive manufacturing area, international business since 1997, and export markets across South America, Africa, Southeast Asia, and the Middle East. Trade records show transactions involving India, Bolivia, and Vietnam, including cefotaxime-related products. Evidence is insufficient to assess after-sales service, financial credibility, innovation output, or customization capability. Customer-case evidence is limited to named buyers and trade records.

Supplier typeThe supplier is identified as a combined business entity and a limited company headquartered in Shandong, China. Its business scope is health and medicine, with products including sterile raw materials, injectable products, tablets, and capsules, supporting classification as a pharmaceutical manufacturer and distributor.

CertificationsThe supplier explicitly reports ISO 9001:2015, ISO 14001:2015, and OHSAS 18001:2007 certificates, and separately describes itself as GMP and ISO authenticated. These stated certifications provide direct evidence of formal quality, environmental, and occupational-health management systems.

Production capacityProduction capacity is supported by more than 10 production lines, three factories, a reported manufacturing area of 1,000,000 square meters, and stated annual output across small-volume injections, powder injections, tablets, and capsules. The supplier also reports annual production above the stated threshold, indicating substantial multi-form pharmaceutical manufacturing capability.

Client casesTrade records identify transactions involving STERILE INDIA PRIVATE LIMITED, HEREDIA ARACENA RENY EVELIN, and a Vietnam-related registration, with products including cefotaxime-related material and oral rehydration products. These records demonstrate some international commercial activity, but the evidence is limited and does not establish long-term customer performance or a broad verified customer portfolio.